Cover Image
市場調查報告書

DNA解旋酶次單位B (EC 5.99.1.3):開發中產品分析

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365786
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
DNA解旋酶次單位B (EC 5.99.1.3):開發中產品分析 DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 24 Pages
簡介

本報告提供以DNA解旋酶次單位B (EC 5.99.1.3)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

DNA翟花邊次單位B (EC 5.99.1.3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Abgentis Limited
  • AstraZeneca Plc
  • 第一三共
  • Merck & Co., Inc.

藥物簡介

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0983TDB

Summary:

DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2017, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Tuberculosis, Acinetobacter Infections, Bacterial Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Klebsiella pneumoniae Infections, Mycobacterium Infections and Neisseria gonorrhoeae Infections.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
  • The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Overview
    • DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Daiichi Sankyo Company Ltd
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles
    • DS-2969 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GYR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA GyrB for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-12008911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXC-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXC-486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products
  • DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
      • May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
Back to Top